RJA
COLL icon

Raymond James & Associates’s Collegium Pharmaceutical COLL Stock Holding History

Raymond James & Associates’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$963K Buy
24,913
+699
+3% +$24.9K ﹤0.01% 2710
2024
Q2 		$780K Buy
24,214
+467
+2% +$16.2K ﹤0.01% 2793
2024
Q1 		$922K Buy
+23,747
New +$831K ﹤0.01% 2647
2019
Q1 		– Sell
-13,216
Closed -$227K – 3636
2018
Q4 		$227K Sell
13,216
-13,862
-51% -$237K ﹤0.01% 3040
2018
Q3 		$399K Sell
27,078
-769
-3% -$13.6K ﹤0.01% 2861
2018
Q2 		$664K Buy
27,847
+5,434
+24% +$134K ﹤0.01% 2493
2018
Q1 		$573K Buy
22,413
+1,329
+6% +$31.7K ﹤0.01% 2479
2017
Q4 		$389K Buy
+21,084
New +$302K ﹤0.01% 2687
2017
Q2 		– Sell
-60,365
Closed -$607K – 3350
2017
Q1 		$607K Sell
60,365
-6,000
-9% -$89.2K ﹤0.01% 2267
2016
Q4 		$1.03M Sell
66,365
-5,550
-8% -$92.2K ﹤0.01% 1906
2016
Q3 		$1.39M Buy
71,915
+3,220
+5% +$38.2K ﹤0.01% 1679
2016
Q2 		$814K Buy
68,695
+27,520
+67% +$455K ﹤0.01% 1845
2016
Q1 		$747K Buy
+41,175
New +$748K ﹤0.01% 1822

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Raymond James & Associates's COLL Position: Q3 2024 in Review

Raymond James & Associates increased its Collegium Pharmaceutical (COLL) stake by 2.9% in Q3 2024, buying an estimated $24.9K and bringing the position to 24,913 shares worth $963K. The position accounts for ﹤0.01% of the portfolio, ranked #2710.

Raymond James & Associates first reported a position in COLL in Q1 2016 and has held it in 13 quarters since. The position peaked at $1.39M in Q3 2016. 249 funds tracked by Wall St. Rank hold COLL as of Q3 2024.

  • Raymond James & Associates held 24,913 shares of Collegium Pharmaceutical worth $963K as of Q3 2024.
  • Raymond James & Associates bought 699 Collegium Pharmaceutical shares in Q3 2024, an estimated $24.9K.
  • Collegium Pharmaceutical made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2710 holding.
  • Raymond James & Associates first reported a position in Collegium Pharmaceutical in Q1 2016 and has held it in 13 quarters since.
  • Raymond James & Associates's Collegium Pharmaceutical position peaked at $1.39M in Q3 2016.
  • 249 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.